Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: A case-control study

AIDS

Volumn 25, Issue 2, 2011, Pages 153-158

  Curlin, Marcel E ^a,b   Cassis Ghavami, Farah ^a   Magaret, Amalia S ^a,c   Spies, Gregory A ^a   Duerr, Ann ^a   Celum, Connie L ^b,c   Sanchez, Jorge L ^d   Margolick, Joseph B ^e   Detels, Roger ^f   McElrath, M Juliana ^a,b,c   Corey, Lawrence ^a,b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Department of Laboratory Medicine ^*  (United States)

^d ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acquisition risk; adenovirus; HIV; MSM; serology; vaccine

Indexed keywords

NEUTRALIZING ANTIBODY;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ADULT; AFRICA; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX VIRUS 2; HETEROSEXUAL FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MORBIDITY; PRIORITY JOURNAL; SEROLOGY; SOUTH AMERICA; UNITED STATES;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ADULT; AFRICA; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CASE-CONTROL STUDIES; FEMALE; GENETIC VECTORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; RISK ASSESSMENT; SOUTH AMERICA; UNITED STATES;

EID: 78650907071     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328342115c     Document Type: Article

References (24)

1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
2. Robb ML. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 2008; 372:1857-1858.
3. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
4. Uberla K. HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection? PLoS Pathog 2008; 4:e1000114.
5. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008; 205:2717-2725.
6. Rodriguez A, Goudsmit J, Companjen A, Mintardjo R, Gil-lissen G, Tax D, et al. Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1. Infect Immun 2008; 76: 1709-1718.
7. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367:475-481.
8. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004; 173:6357-6365.
9. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-609.
10. Diseases NIoAaI. Bulletin: HVTN 505 HIV vaccine study begins enrolling volunteers. NIAID news & events: news releases: NIAID; 2009 (news release).
11. Baden L, Dolin R, O'Brien K, Abbink P, La Porte A, Seaman M, et al. OA05-06 LB. First-in-human phase 1 safety and immu-nigenicity of an adenovirus serotype 26 HIV-1 vaccine vector. Retrovirology 2009; 6:O36.
12. Steinbrook R. One step forward, two steps back: will there ever be an AIDS vaccine? N Engl J Med 2007; 357:2653-2655.
13. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science 2008; 321:530-532.
14. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205:7-12.
15. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, et al. Replication-deficient human adeno-virus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263-8271.
16. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogeni-city of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81:4654-4663.
17. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006; 44:3781-3783.
18. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV- 1vaccinecandidateinhumans.NatMed2009;15:873-875.
19. Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, Kierstead L, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4R T cells. Nat Med 2009; 15:876-878.
20. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-318.
21. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Mor-etlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
22. Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK, et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 2004; 15:293-304.
23. Corey L, McElrath MJ, Kublin JG. Poststep modifications for research on HIV vaccines. AIDS 2009; 23:3-8.
24. Buchbinder S. Efficacy results from the Step Study (Merck V520 Protocol 023/HVTN 502): a phase II test-of-concept trial of the MRKAd5 HIV-1Gag/Pol/Nef Trivalent Vaccine. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Hynes Convention Center; 2008.